Patents Assigned to ALTIF Laboratories
  • Polynucleotides encoding proteins having acquired ?-galactosidase activity
    Patent number: 9315790
    Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 19, 2016
    Assignees: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, ALTIF LABORATORIES INC.
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Ikuo Kawashima, Seiichi Aikawa, Fumiko Aikawa
  • Highly functional enzyme having alpha-galactosidase activity
    Patent number: 9193964
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: November 24, 2015
    Assignees: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, ALTIF LABORATORIES
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
  • HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY
    Publication number: 20140171493
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: January 23, 2014
    Publication date: June 19, 2014
    Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
  • Highly functional enzyme having ?-galactosidase activity
    Patent number: 8668907
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 11, 2014
    Assignees: Tokyo Metropolitan Institute of Medical Science, Altif Laboratories
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
  • PROTEINS HAVING ACQUIRED A-GALACTOSIDASE ACTIVITY
    Publication number: 20140044699
    Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: September 13, 2013
    Publication date: February 13, 2014
    Applicants: ALTIF LABORATORIES INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Hitoshi SAKURABA, Youichi TAJIMA, Ikuo KAWASHIMA, Seiichi AIKAWA, Fumiko AIKAWA
  • Proteins having acquired A-galactosidase activity
    Patent number: 8569032
    Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: October 29, 2013
    Assignees: Tokyo Metropolitan Institute of Medical Science, ALTIF Laboratories Inc.
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Ikuo Kawashima, Seiichi Aikawa, Fumiko Aikawa
  • HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY
    Publication number: 20130064805
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: November 2, 2012
    Publication date: March 14, 2013
    Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
    Inventors: TOKYO METROPOLITAN ORGANIZATION FOR, ALTIF LABORATORIES
  • Highly functional enzyme having ?-galactosidase activity
    Patent number: 8323640
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: December 4, 2012
    Assignees: Tokyo Metropolitan Organization For Medical Research, Altif Laboratories
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
  • HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY
    Publication number: 20110171198
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 14, 2011
    Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIES
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
  • Highly functional enzyme having ?-galactosidase activity
    Patent number: 7935336
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: May 3, 2011
    Assignees: Tokyo Metropolitan Organization for Medical Research, ALTIF Laboratories
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
  • PHARMACEUTICAL COMPOSITION FOR ENZYME REPLACEMENT THERAPY
    Publication number: 20100291059
    Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: May 19, 2008
    Publication date: November 18, 2010
    Applicants: ALTIF LABORATORIES INC.
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Ikuo Kawashima, Seiichi Aikawa, Fumiko Aikawa
  • Novel Highly Functional Enzyme Having Modified Substrate-Specificity
    Publication number: 20100166728
    Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
    Type: Application
    Filed: November 17, 2006
    Publication date: July 1, 2010
    Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIES
    Inventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa